Amazon Biotech Inc. in Advanced Negotiations to Obtain Approvals for Sale of Its AIDS Drug in Nigeria and Kenya
Tuesday , December 19, 2006 16:30ET
NEW YORK, NY -- (MARKET WIRE) -- 12/19/06 -- Amazon Biotech, Inc. (OTCBB: AMZB) (FRANKFURT: B2D), announced today that it is in negotiations with a European company to obtain approvals for sale of its AIDS drug in Nigeria and Kenya.
Dr. Mechael Kanovsky, President of Amazon Biotech Inc., stated: "Obtaining these licenses will be an important step for the company. We believe that our drug will have a positive impact on the AIDS epidemic in Africa."
About Amazon Biotech, Inc.
Amazon Biotech, Inc. is a natural plant pharmaceutical company, primarily developing immune modulator drugs. AMZ0026 is the company's first such drug, which is to be used for the treatment of HIV/AIDS. The company plans on initiating Phase I/II clinical studies of AMZ0026 in the near future, with an eventual goal of attracting a joint venture partner with a major pharmaceutical company in Phase III trials, or following the FDA Fast Track program to market. Amazon Biotech specializes in natural plant pharmaceutical drugs and is focused on bringing healthier pharmaceutical drugs to market.
"Safe-Harbor" Statement Under the Private Securities Litigation Reform Act of 1995. This press release contains forward-looking information within the meaning of Section 21E of the Securities Exchange Act of 1934, including statements regarding any potential sales of products as well as statements that include the words "believes," "expects," "anticipates," or similar expressions. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements of Amazon Biotech, to differ materially from those implied or expressed by such forward-looking statements. Such factors include, among others, the risk factors included in Amazon Biotech's subsequent reports filed with the Securities and Exchange Commission under the Exchange Act. This press release speaks as of the date first set forth above and Amazon Biotech assumes no responsibility to update the information included herein for events occurring after the date hereof.
-------------------------------------------------------------------------------- Contact: LC Group Rick Lutz (404) 261-1196
Source: Amazon Biotech, Inc
-------------------- " Cash is King "
IP: Logged |
quote:Originally posted by Average Joe: Several websites that I subscribe to also going with AMZB today. We could get a nice run this morning .... IMHO
I saw a few too Joe. Let's hope for some GREEN today.
-------------------- " I'm in the trenches taking grenades "
IP: Logged |
posted
I got emails last nite from some pump&dump group on AMZB. That big volume on Mon. and Tue. was obviously them buying and dumping it this morning when the price rose 25-30% from Mon. and Tue. levels. No way this stock should have tanked on this news.
-------------------- " Cash is King "
IP: Logged |
posted
Here's one of them just in case you think I'm giving you some BS :
From: info*******.com To: Average Joe Cc: Bcc: Subject: ******.com - AMZB could change the world Date: Tue, 19 Dec 2006 8:15 PM
Watch List for Wednesday 12-20-2006
My new big pick is AMZB.
I believe the first company that comes up with a cure for AIDS will become the biggest company in the world. AMZB definitely looks like it's on the right track.
AIDS is a serious disease that can't be stopped and the way it's spreading is very alarming!!
AMZB's main product right now is AMZ0026, a therapeutic herbal composition, is currently approved by the FDA to undergo Phase I/II studies in humans. AMZ0026 has been shown to exhibit potential therapeutically beneficial effects on the immune system of immunodeficient HIV/AIDS patients, particularly with respect to elevation of CD4 levels in preliminary clinical case studies.
The CD4 or T-helper Cell is what the AIDS/HIV virus attacks. AMZB's current drug has been shown to improve these levels. I believe these results can be compared to the invention of the wheel!!!
Perhaps one day AMZB could turn out to be a huge pharmaceutical company like Amgen.
AMZB has a 52wk high of .36 so at it's current levels and recent news it looks extremely undervalued.
AMZB's main drug is the result of 15 years or work and an investment of over $15 million.
Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. *********************************************************
-------------------- " Cash is King "
IP: Logged |
quote:Originally posted by JBURNS: It looks like to me, that they did the same thing with HYPF today.
Hey JB ... I've been getting HYPF emails for awhile now. They had a nice run but, they are played out. From .09 to .51 in a couple of days and now back into the 20's. Eventually these PR companies start selling the stock they were paid and the price has to go down.
-------------------- " Cash is King "
IP: Logged |
posted
If you read the disclaimers on these PR companies the legit ones will state if they were paid in cash or shares. If they were paid in cash, no problem. If they were paid in shares, here is where the problem lies. If done properly, they can dispose of their shares over a period of time as not to hurt the stock or their subscribers. It's the pump&dump group who dumps their shares after/while their subscribers are buying, regardless of what it does to the stock price. They screw the company they are promoting and leave their subscribers holding the bag. I have one website in particular that I have done quite well with but nothing is foolproof.
-------------------- " Cash is King "
IP: Logged |
UBBFriend: Email this page to someone!
Printer-friendly view of this topic
